Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]
Comparative Effectiveness Research · 2018
DOI: 10.2147/cer.s151220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Comparative Effectiveness Research, 2018. Verfasst von Jian Li und 7 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Li, J., Ren, H. Y., Zhang, J., Dong, P., Wang, Y., Stevens, A., Han, Y., & Huang, M. (2018). Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]. Comparative Effectiveness Research. https://doi.org/10.2147/cer.s151220
Vancouver
Li J, Ren HY, Zhang J, Dong P, Wang Y, Stevens A, et al. Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]. Comparative Effectiveness Research. 2018. doi:10.2147/cer.s151220
BibTeX
@article{Li2018,
author = {Li, Jian and Ren, Hong Ye and Zhang, Juanjuan and Dong, Peng and Wang, Yan and Stevens, Andrea and Han, Yi and Huang, Min},
title = {Cost-effectiveness of sunitinib as second-line treatment for gastrointestinal stromal tumor in the People’s Republic of China [Corrigendum]},
journal = {Comparative Effectiveness Research},
year = {2018},
doi = {10.2147/cer.s151220}
}
EUVIMED